Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Baxter
Merck
Johnson and Johnson
Medtronic

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TENOFOVIR DISOPROXIL FUMARATE

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Tenofovir Disoproxil Fumarate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002450 Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients Completed Gilead Sciences Phase 3 1969-12-31 The purpose of this study is to see if giving tenofovir DF plus a combination of other anti-HIV drugs is safe and effective.
NCT00002453 A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection Completed Gilead Sciences N/A 1999-12-01 This study allows patients who need a new anti-HIV treatment to take tenofovir disoproxil fumarate (tenofovir DF), an experimental drug. This study also looks at any side effects the drug causes.
NCT00007436 The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients Unknown status Gilead Sciences Phase 3 1969-12-31 The purpose of this study is to evaluate the safety of tenofovir disoproxil fumarate (tenofovir DF) in combination with other anti-HIV drugs in patients who have participated in other tenofovir DF studies (GS-98-902 or GS-99-907), are able to tolerate the drug at different doses, and may benefit from having tenofovir DF treatment.
NCT00011089 Tenofovir Disoproxil Fumarate in HIV-Infected Patients Who Have Not Had Success With Other Anti-HIV Drug Combinations Unknown status Gilead Sciences N/A 2001-02-01 The purpose of this study is to make tenofovir disoproxil fumarate (DF) available to HIV-infected patients who have failed other anti-HIV drug combinations, who have few treatment choices available, and whose disease may get worse. This study will allow patients to obtain tenofovir DF before it is approved for marketing.
NCT00013520 Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 1969-12-31 The purpose of this study is to compare the effectiveness, safety, and tolerability of 3 anti-HIV combination treatments that do not use protease inhibitors (PIs). The current rule for starting treatment of HIV infection is to combine members from different classes of anti-HIV drugs, such as 2 nucleoside reverse transcriptase inhibitors (NRTIs) and either a PI or a nonnucleoside reverse transcriptase inhibitor (NNRTI). However, these combinations can be complicated and difficult to take, can cause a number of side effects, and may become ineffective. Combinations that are simpler, better tolerated, and more effective are needed. Because PIs can cause long-term side effects and because HIV can become resistant to many of them at the same time, anti-HIV combination treatments that do not use PIs are being tested.
NCT00016588 Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs Completed Gilead Sciences N/A 2001-05-01 The purpose of this study is to look at the effectiveness of tenofovir disoproxil fumarate (TDF) in HIV-infected patients who have never taken anti-HIV drugs.
NCT00024986 Tenofovir Disoproxil Fumarate to Treat Pediatric HIV Completed National Cancer Institute (NCI) Phase 1 2001-10-01 This study will test the safety, side effects and antiviral activity of different doses of tenofovir DF in children and adolescents with human immunodeficiency virus (HIV) infection. Tenofovir DF belongs to a group of drugs called nucleotide analog reverse transcriptase inhibitors. These drugs prevent the virus from replicating (making more copies of itself). HIV becomes resistant to many drugs used to fight the virus and these drugs become ineffective. In laboratory tests, tenofovir DF has remained effective against HIV longer than other anti-HIV medicines, and when resistance does develop, the virus may still be sensitive to other drugs. HIV-infected children between the ages of 4 and 18 years who weigh at least 10 kg (22 pounds) may be eligible for this study. They must be able to receive antiretroviral therapy and have completed at least two previous antiretroviral courses of treatment without benefit. Upon entering the study, participants will have physical, eye and neuropsychiatric examinations, blood tests, including tests to determine what anti-HIV drugs the patient is resistant to, an echocardiogram (echo), electrocardiogram (EKG), chest X-ray, head CT scan, skin tests, and special tests to examine the bones. These physical exams and tests will be repeated throughout the study to determine changes in health. Participants will continue their current anti-HIV therapy for 2 weeks and then stop all medicines for a 1-week 'washout' period. After the washout period, patients will begin taking tenofovir DF. For the first 2 days on the drug, a small blood sample (1/2 teaspoon) will be collected 11 times over a 48-hour period through. A heparin lock (a tube kept in place in a vein) may be put in place to avoid multiple needle sticks. Blood samples will be collected for another 4 days to measure how well tenofovir DF alone works against HIV before other drugs are added to the treatment regimen. After these first 6 days, at least two other anti-HIV drugs will be added. They will be selected based on the results of the earlier blood tests for resistance and on the child's medication history. After 3 days of combination therapy, patients will continue therapy on an outpatient basis. They will be seen in the clinic every 4 weeks at the start of the study and then every 12 weeks for physical exams, lab tests and other procedures as needed. The study will last approximately 48 weeks. Patients who benefit from therapy may be able to continue to receive tenofovir DF from the drug company sponsor or as part of another study, or the protocol for this study may be amended to lengthen the treatment period.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Tenofovir Disoproxil Fumarate

Condition Name

Condition Name for Tenofovir Disoproxil Fumarate
Intervention Trials
HIV Infections 97
HIV 38
Chronic Hepatitis B 36
Hepatitis B 20
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Tenofovir Disoproxil Fumarate
Intervention Trials
HIV Infections 132
Hepatitis 87
Hepatitis B 84
Hepatitis A 69
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Tenofovir Disoproxil Fumarate

Trials by Country

Trials by Country for Tenofovir Disoproxil Fumarate
Location Trials
China 119
Canada 108
United Kingdom 55
Australia 52
Germany 48
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Tenofovir Disoproxil Fumarate
Location Trials
California 95
New York 77
Florida 66
Texas 60
North Carolina 55
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Tenofovir Disoproxil Fumarate

Clinical Trial Phase

Clinical Trial Phase for Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Phase 4 75
Phase 3 81
Phase 2/Phase 3 8
[disabled in preview] 91
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Tenofovir Disoproxil Fumarate
Clinical Trial Phase Trials
Completed 145
Recruiting 50
Active, not recruiting 47
[disabled in preview] 58
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Tenofovir Disoproxil Fumarate

Sponsor Name

Sponsor Name for Tenofovir Disoproxil Fumarate
Sponsor Trials
Gilead Sciences 104
National Institute of Allergy and Infectious Diseases (NIAID) 58
Merck Sharp & Dohme Corp. 15
[disabled in preview] 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Tenofovir Disoproxil Fumarate
Sponsor Trials
Other 247
Industry 191
NIH 76
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Baxter
Boehringer Ingelheim
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.